Actively Recruiting
A Study Evaluating the Value of 68Ga-NOTA-RCCB6 PET Imaging for Targeting CD70 in the Clinical Staging, Therapeutic Evaluation, and Restaging of Renal Cell Carcinoma, and Comparing It with 68Ga-PSMA PET/CT Imaging
Led by Xijing Hospital · Updated on 2025-01-10
60
Participants Needed
1
Research Sites
73 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a prospective, open-label, single-center clinical study targeting renal cell carcinoma. Sixty patients with a high clinical suspicion of renal cell carcinoma were included. Qualified subjects will undergo 68Ga-NOTA-RCCB6 PET/CT examination. The aim is to establish the optimal imaging protocol; evaluate the distribution characteristics and correlations of physiological and pathological positive uptake, and using pathological results as the gold standard, assess the diagnostic efficacy of 68Ga-NOTA-RCCB6 PET/CT in renal cell carcinoma.
CONDITIONS
Official Title
A Study Evaluating the Value of 68Ga-NOTA-RCCB6 PET Imaging for Targeting CD70 in the Clinical Staging, Therapeutic Evaluation, and Restaging of Renal Cell Carcinoma, and Comparing It with 68Ga-PSMA PET/CT Imaging
Who Can Participate
Eligibility Criteria
You may qualify if you...
- The subject or legal guardian/caregiver must voluntarily sign the informed consent form.
- Aged 18 to 75 years old.
- Patients with suspected renal cell carcinoma based on conventional imaging studies.
- Patients who have undergone 68Ga-PSMA PET/CT scanning.
- Patients with suspicious lymph nodes or distant metastases detected by conventional imaging or 68Ga-PSMA PET/CT.
- Willing and able to follow the study protocol.
You will not qualify if you...
- Patients who have received anti-tumor treatment prior to PET/CT scan.
- Patients with severe neurological, gastrointestinal, cardiovascular, liver, kidney, blood system, respiratory system, immunodeficiency, or other serious diseases.
- Patients with contraindications to PET/CT scanning, including inability to tolerate repeated intravenous injections or allergy to the drug or its components.
- Patients with claustrophobia.
- Diagnosed with other malignant tumors within the past year.
- Underwent major surgery within the past 3 months.
- Received experimental drug or device treatment with unclear effects or safety within the past month.
- Participated in other interventional clinical trials within the past month.
- Pregnant or lactating women.
- Patients who are lost to follow-up.
- Other conditions that may affect the study or make the subject unsuitable, as assessed by the researcher.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department ofNuclear Medicine,Xijing Hospital, Fourth Military Medical University, Xi'an, China
Xi'an, China, Shaanxi, China, 710000
Actively Recruiting
Research Team
Y
Ying Guo
CONTACT
H
he rui Li
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here